Amgen – Unresected Stage IIIB to IVM1c Melanoma

Access Program Information

The study is a phase 3b, multicenter, open-label, single-arm study designed to provide
expanded access of Talimogene Laherparepvec for the treatment of subjects with unresected
stage IIIB to IVM1c melanoma. The study will also evaluate the safety and tolerability of
Talimogene Laherparepvec.